Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows:

Date: Tuesday, August 9, 2022

Time: 1:30 p.m. Pacific / 4:30 p.m. Eastern

Toll-free: (800) 715-9871

Conference ID: 4116795

Webcast URL: http://investor.neoleukin.com/events

The archived audio webcast will be available on the Investor Relations section of the Neoleukin website approximately two hours after the event and will be available for replay for at least 30 days after the event.

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.

Contacts:

Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com

Investors
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com

Staff

Recent Posts

Veradigm Recognized with KLAS 2025 Points of Light Award for Optimizing Value-Based Care

Delivering insights at the point-of-care to close quality care gaps resulted in a time savings…

52 minutes ago

Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD)

Companies will collaborate on an AI-powered care improvement solution for patients with high-risk COPD SAN…

57 minutes ago

Hemostemix Presents at TERMIS 2025, Freiburg, Germany

Freiburg, Germany--(Newsfile Corp. - May 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a…

1 hour ago

Mobile-health Network Solutions Signs MOU to Add AI-enabled Dental Scans and Oral Health Screening to its Telemedicine Platform

Singapore, Singapore--(Newsfile Corp. - May 20, 2025) - Mobile-health Network Solutions (Nasdaq: MNDR) ("MNDR" or…

1 hour ago

Promino Nutritional Sciences Inc. Comments on Trading Halt

Burlington, Ontario--(Newsfile Corp. - May 20, 2025) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC…

3 hours ago

SIME Diagnostics Announces Results of Clinical Study on AI-Powered Lung Maturity Test in U.S. Neonatal Intensive Care Unit

LONDON  and ROCHESTER, Minn., May 20, 2025 /PRNewswire/ -- SIME Diagnostics, a UK-based medical technology company…

4 hours ago